Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Discovery and characterization of selective small molecule inhibitors of the mammalian mitochondrial division dynamin, DRP1.

Mallat A, Uchiyama LF, Lewis SC, Fredenburg RA, Terada Y, Ji N, Nunnari J, Tseng CC.

Biochem Biophys Res Commun. 2018 May 15;499(3):556-562. doi: 10.1016/j.bbrc.2018.03.189. Epub 2018 Apr 4.

2.

Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.

Lagu B, Kluge AF, Goddeeris MM, Tozzo E, Fredenburg RA, Chellur S, Senaiar RS, Jaleel M, Babu DRK, Tiwari NK, Takahashi T, Patane MA.

Bioorg Med Chem Lett. 2018 Feb 1;28(3):533-536. doi: 10.1016/j.bmcl.2017.11.006. Epub 2017 Nov 4.

PMID:
29275935
3.

Novel highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulators with pharmacokinetic properties suitable for once-daily oral dosing.

Lagu B, Kluge AF, Fredenburg RA, Tozzo E, Senaiar RS, Jaleel M, Panigrahi SK, Tiwari NK, Krishnamurthy NR, Takahashi T, Patane MA.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5230-5234. doi: 10.1016/j.bmcl.2017.10.037. Epub 2017 Oct 27.

PMID:
29103972
4.

Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A.

Jacobson AR, Adler M, Silvaggi NR, Allen KN, Smith GM, Fredenburg RA, Stein RL, Park JB, Feng X, Shoemaker CB, Deshpande SS, Goodnough MC, Malizio CJ, Johnson EA, Pellett S, Tepp WH, Tzipori S.

Toxicon. 2017 Oct;137:36-47. doi: 10.1016/j.toxicon.2017.06.016. Epub 2017 Jul 8.

5.

Development and advanced validation of an optimized method for the quantitation of Aβ42 in human cerebrospinal fluid.

Cullen VC, Fredenburg RA, Evans C, Conliffe PR, Solomon ME.

AAPS J. 2012 Sep;14(3):510-8. doi: 10.1208/s12248-012-9360-7. Epub 2012 May 3.

6.

Botulinum neurotoxin serotype A inhibitors: small-molecule mercaptoacetamide analogs.

Moe ST, Thompson AB, Smith GM, Fredenburg RA, Stein RL, Jacobson AR.

Bioorg Med Chem. 2009 Apr 15;17(8):3072-9. doi: 10.1016/j.bmc.2009.03.013. Epub 2009 Mar 14.

7.

Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.

Liu Z, Meray RK, Grammatopoulos TN, Fredenburg RA, Cookson MR, Liu Y, Logan T, Lansbury PT Jr.

Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4635-40. doi: 10.1073/pnas.0806474106. Epub 2009 Mar 4.

8.

Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein.

Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA, Lansbury PT Jr, Fernandez CO, Eliezer D, Zweckstetter M, Lashuel HA.

J Biol Chem. 2008 Jun 13;283(24):16895-905. doi: 10.1074/jbc.M800747200. Epub 2008 Mar 14.

9.

The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states.

Fredenburg RA, Rospigliosi C, Meray RK, Kessler JC, Lashuel HA, Eliezer D, Lansbury PT Jr.

Biochemistry. 2007 Jun 19;46(24):7107-18. Epub 2007 May 26.

PMID:
17530780
10.

Molecular cloning and sequence analysis of the complestatin biosynthetic gene cluster.

Chiu HT, Hubbard BK, Shah AN, Eide J, Fredenburg RA, Walsh CT, Khosla C.

Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8548-53. Epub 2001 Jul 10.

11.

Method for reducing endotoxin in Moraxella catarrhalis UspA2 protein preparations.

Fiske MJ, Fredenburg RA, VanDerMeid KR, McMichael JC, Arumugham R.

J Chromatogr B Biomed Sci Appl. 2001 Apr 5;753(2):269-78.

PMID:
11334340
12.

Isolation and characterization of two proteins from Moraxella catarrhalis that bear a common epitope.

McMichael JC, Fiske MJ, Fredenburg RA, Chakravarti DN, VanDerMeid KR, Barniak V, Caplan J, Bortell E, Baker S, Arumugham R, Chen D.

Infect Immun. 1998 Sep;66(9):4374-81.

Supplemental Content

Loading ...
Support Center